HIV-Specific CD8+ T Cells from Elite Controllers Are Primed for Survival

被引:38
|
作者
Yan, Jiyu [1 ]
Sabbaj, Steffanie [1 ]
Bansal, Anju [1 ]
Amatya, Nilesh [1 ]
Shacka, John J. [3 ]
Goepfert, Paul A. [1 ,2 ]
Heath, Sonya L. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; VIRAL LOAD; IMMUNE ACTIVATION; PERIPHERAL-BLOOD; CUTTING EDGE; CLASS-I; RESPONSES; APOPTOSIS; INFECTION;
D O I
10.1128/JVI.02379-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-specific cytotoxic T lymphocytes (CTL) are preferentially primed for apoptosis, and this may represent a viral escape mechanism. We hypothesized that HIV-infected individuals that control virus to undetectable levels without antiretroviral therapy (ART) (elite controllers [EC]) have the capacity to upregulate survival factors that allow them to resist apoptosis. To address this, we performed cross-sectional and longitudinal analysis of proapoptotic (cleaved caspase-3) and antiapoptotic (Bcl-2) markers of cytomegalovirus (CMV) and HIV-specific CD8 T cells in a cohort of HIV-infected subjects with various degrees of viral control on and off ART. We demonstrated that HIV-specific CTL from EC are more resistant to apoptosis than those with pharmacologic control (successfully treated patients [ST]), despite similar in vivo conditions. Longitudinal analysis of chronically infected persons starting ART revealed that the frequency of HIV-specific T cells prone to death decreased, suggesting that this phenotype is partially reversible even though it never achieves the levels present in EC. Elucidating the apoptotic factors contributing to the survival of CTL in EC is paramount to our development of effective HIV-1 vaccines. Furthermore, a better understanding of cellular markers that can be utilized to predict response durability in disease- or vaccine-elicited responses will advance the field.
引用
收藏
页码:5170 / 5181
页数:12
相关论文
共 50 条
  • [41] Survival defects and skewed memory phenotype of HIV-specific CD8+ T cells are detectable in early clinical stages of chronic HIV infection
    Mueller, Yvonne M.
    Petrovas, Constantinos
    Altork, Susan R.
    Saini, Jaspreet
    Pitsakis, Peter
    Mounzer, Karam C.
    Altman, John D.
    Katsikis, Pete D.
    JOURNAL OF NEUROVIROLOGY, 2006, 12 : 56 - 57
  • [42] HIV-specific CD4+ T-cells may contribute to viral persistence in HIV-infected elite controllers
    Hunt, P. W.
    Hatano, H.
    Sinclair, E.
    Delwart, E. L.
    Lee, T. H.
    Busch, M. P.
    Hoh, R.
    Grossman, Z.
    Martin, J. N.
    Deeks, S. G.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A7 - A7
  • [43] Identification and characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue
    Buggert, Marcus
    Son Nguyen
    de Oca, Gonzalo Salgado-Montes
    Bengsch, Bertram
    Darko, Samuel
    Ransier, Amy
    Roberts, Emily R.
    del Alcazar, Daniel
    Brody, Irene Bukh
    Vella, Laura A.
    Beura, Lalit
    Wijeyesinghe, Sathi
    Herati, Ramin S.
    Estrada, Perla M. Del Rio
    Ablanedo-Terrazas, Yuria
    Kuri-Cervantes, Leticia
    Japp, Alberto Sada
    Manne, Sasikanth
    Vartanian, Shant
    Huffman, Austin
    Sandberg, Johan K.
    Gostick, Emma
    Nadolski, Gregory
    Silvestri, Guido
    Canaday, David H.
    Price, David A.
    Petrovas, Constantinos
    Su, Laura F.
    Vahedi, Golnaz
    Dori, Yoav
    Frank, Ian
    Itkin, Maxim G.
    Wherry, E. John
    Deeks, Steven G.
    Naji, Ali
    Reyes-Teran, Gustavo
    Masopust, David
    Douek, Daniel C.
    Betts, Michael R.
    SCIENCE IMMUNOLOGY, 2018, 3 (24)
  • [44] NKG2D Expression on HIV-Specific CD8+ T cells Is Reduced in Viremic HIV-1-Infected Patients but Maintained in HIV Controllers
    Lecuroux, Camille
    Saez-Cirion, Asier
    Noel, Nicolas
    Ben-Lamine, Lilia
    Girault, Isabelle
    Caillat-Zucman, Sophie
    Scott-Algara, Daniel
    Venet, Alain
    Lambotte, Olivier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (01) : 17 - 20
  • [45] Correction: Corrigendum: Protective HIV-specific CD8+ T cells evade Treg cell suppression
    Shokrollah Elahi
    Warren L Dinges
    Nicholas Lejarcegui
    Kerry J Laing
    Ann C Collier
    David M Koelle
    M Juliana McElrath
    Helen Horton
    Nature Medicine, 2011, 17 : 1153 - 1153
  • [46] Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors
    Vieira, Vinicius A.
    Millar, Jane
    Adland, Emily
    Muenchhoff, Maximilian
    Roider, Julia
    Guash, Claudia Fortuny
    Peluso, Denise
    Thome, Beatriz
    Garcia-Guerrero, Maria C.
    Puertas, Mari C.
    Bamford, Alasdair
    Brander, Christian
    Carrington, Mary
    Martinez-Picado, Javier
    Frater, John
    Tudor-Williams, Gareth
    Goulder, Philip
    AIDS, 2022, 36 (01) : 95 - 105
  • [47] HIV subtypes induce distinct profiles of HIV-specific CD8+ T cell responses
    Baker, Chris A. R.
    McEvers, Kimberly
    Byaruhanga, Rose
    Mulindwa, Rwabaingi
    Atwine, Diana
    Nantiba, Josephine
    Jones, Norman G.
    Ssewanyana, Isaac
    Cao, Huyen
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 (02) : 283 - 287
  • [48] Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers
    Chowdhury, Fatema Z.
    Ouyang, Zhengyu
    Buzon, Maria
    Walker, Bruce D.
    Lichterfeld, Mathias
    Yu, Xu G.
    AIDS, 2018, 32 (18) : 2669 - 2677
  • [49] HIV "Elite Controllers" Are Characterized by a High Frequency of Memory CD8+CD73+ T Cells Involved in the Antigen-Specific CD8+ T-cell Response
    Carriere, Matthieu
    Lacabaratz, Christine
    Koek, Ayrin
    Benne, Clarisse
    Jenabian, Mohammad-Ali
    Casartelli, Nicoletta
    Huee, Sophie
    Hocqueloux, Laurent
    Lelievre, Jean-Daniel
    Levy, Yves
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (09): : 1321 - 1330
  • [50] CD8+ T-CELLS FROM HIV-INFECTED PATIENTS CAN EITHER AUGMENT OR ABROGATE HIV-SPECIFIC LYMPHOPROLIFERATION
    BELL, SJD
    COOPER, DA
    KEMP, BE
    DOHERTY, RR
    PENNY, R
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 64 (03): : 254 - 260